H1 shows a continuing move towards Bio-Medical, with that division now delivering 57% of group revenue. Overall, a challenging first half year was as expected, but improved margins and tight cost control reduced the loss and a much stronger second half is flagged in the outlook. There is thus no change to FY 2016 guidance or forecasts. Following its $3.8m acquisition of Green Lab in January, but before receipt of the $3.0m Egens investment in Adaltis, BATM ended June with a healthy $14.0m net ....